Answer
Rash is very common (affecting at least 1 in 10 patients) with tucatinib plus trastuzumab and capecitabine, based on studies in locally advanced unresectable or metastatic HER2-positive breast cancer.
Sources for this answer
- TUKYSA 50 mg film-coated tabletPfizer Limited · emc · SmPC §4.8 Undesirable effects · Version 6Document updated
Sources checked